We are live on ! Find out more
PCM

Prelude Capital Management Portfolio holdings

AUM $1.31B
1-Year Est. Return 62.02%
This Fund
S&P 500
This Quarter Est. Return
+9.06%
1 Year Est. Return
+62.02%
3 Year Est. Return
+164.16%
5 Year Est. Return
+274.13%
10 Year Est. Return
+2,470.2%
AUM
$1.65B
AUM Growth
+$213M
Cap. Flow
+$127M
Cap. Flow %
7.68%
Top 10 Hldgs %
13.99%
Holding
1,616
New
434
Increased
384
Reduced
359
Closed
375

Top Buys

Rank Stock Value
1
ESTC icon
Elastic
ESTC
+$6.65M
2
K
Kellanova
K
+$6.45M
3
CORZ icon
Core Scientific
CORZ
+$5.85M
4
BITO icon
ProShares Bitcoin Strategy ETF
BITO
+$5.79M
5
GTM
ZoomInfo Technologies
GTM
+$5.61M

Top Sells

Rank Stock Value
1
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
+$11.1M
2
WDC icon
Western Digital
WDC
+$8.43M
3
HLIT icon
Harmonic Inc
HLIT
+$7.72M
4
NTES icon
NetEase
NTES
+$7.33M
5
FTRE icon
Fortrea Holdings
FTRE
+$6.96M

Sector Composition

Rank Sector Weight
1 Technology 14.94%
2 Consumer Discretionary 9.59%
3 Healthcare 9.5%
4 Industrials 8.56%
5 Communication Services 6.47%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SGMT icon
1201
Sagimet Biosciences
SGMT
$574M
$58.7K ﹤0.01%
21,200
+8,900
+72% +$27.4K
DCGO icon
1202
DocGo
DCGO
$57.6M
$58.4K ﹤0.01%
17,600
+2,800
+19% +$9.52K
INMB icon
1203
INmune Bio
INMB
$58M
$57.8K ﹤0.01%
+10,727
New +$76.3K
ACET icon
1204
Adicet Bio
ACET
$74.9M
$57.6K ﹤0.01%
+2,499
New +$55.9K
ESPR
1205
CALL
DELISTED
Esperion Therapeutics
ESPR
$57.4K ﹤0.01%
+34,800
New +$70.3K
CHGG icon
1206
Chegg
CHGG
$96.8M
$56.5K ﹤0.01%
31,900
-3,134
-9% -$7.68K
ZNTL icon
1207
Zentalis Pharmaceuticals
ZNTL
$292M
$56K ﹤0.01%
+15,210
New +$55.3K
PMVP icon
1208
PMV Pharmaceuticals
PMVP
$63.5M
$55.3K ﹤0.01%
37,100
-97,600
-72% -$151K
ADV icon
1209
Advantage Solutions
ADV
$368M
$55K ﹤0.01%
641
-348
-35% -$32.1K
CRBU icon
1210
Caribou Biosciences
CRBU
$164M
$54.9K ﹤0.01%
28,010
+1,600
+6% +$3.28K
RCAT icon
1211
Red Cat Holdings
RCAT
$1.51B
$54K ﹤0.01%
+21,278
New +$50.7K
GILT icon
1212
Gilat Satellite Networks
GILT
$835M
$53.6K ﹤0.01%
+10,172
New +$46.8K
BCAB icon
1213
BioAtla
BCAB
$5.74M
$53.5K ﹤0.01%
+608
New +$51K
ACCD
1214
DELISTED
Accolade Inc
ACCD
$50.2K ﹤0.01%
+13,042
New +$51.1K
SLND icon
1215
Southland Holdings
SLND
$33.3M
$46.7K ﹤0.01%
+12,612
New +$49.2K
MAPS
1216
DELISTED
WM TECHNOLOGY INC A
MAPS
$46.3K ﹤0.01%
53,265
-28,712
-35% -$28.6K
VTYX
1217
DELISTED
Ventyx Biosciences
VTYX
$45.8K ﹤0.01%
21,000
+8,900
+74% +$20.5K
OABI icon
1218
OmniAb
OABI
$491M
$45.1K ﹤0.01%
10,670
-6,655
-38% -$28.8K
TLRY icon
1219
Tilray
TLRY
$592M
$42.1K ﹤0.01%
2,390
– –
MXCT icon
1220
MaxCyte
MXCT
$129M
$41.6K ﹤0.01%
+10,700
New +$45.1K
SAVE
1221
PUT
DELISTED
Spirit Airlines, Inc.
SAVE
$41.3K ﹤0.01%
17,200
+1,500
+10% +$4.13K
STRO icon
1222
Sutro Biopharma
STRO
$422M
$40.4K ﹤0.01%
1,169
-1,830
-61% -$71.7K
CURV icon
1223
Torrid Holdings
CURV
$253M
$39.8K ﹤0.01%
+10,117
New +$68.1K
BOLD
1224
Boundless Bio
BOLD
$65.2M
$38.3K ﹤0.01%
+11,024
New +$40K
WHWK
1225
Whitehawk Therapeutics
WHWK
$262M
$36.7K ﹤0.01%
17,797
-18,400
-51% -$29.7K
47 48
49
50 51

Similar funds

PFBT
Parkside Financial Bank & Trust Saint Louis, Missouri $1.31B AUM 19.14% 1-Year Est. Return
CCP
Clarkston Capital Partners Rochester, Michigan $1.31B AUM 3.79% 1-Year Est. Return
SP
Sherman Porfolios Coeur D'alene, Idaho $1.3B AUM 35.18% 1-Year Est. Return
HCS
Himension Capital (Singapore) Singapore $1.3B AUM 85.53% 1-Year Est. Return
SPC
Silver Point Capital Greenwich, Connecticut $1.3B AUM 18.3% 1-Year Est. Return
GPCM
Greenbrier Partners Capital Management Dallas, Texas $1.3B AUM 21.43% 1-Year Est. Return
MCM
Mainstay Capital Management Grand Blanc, Michigan $1.3B AUM 37.8% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Prelude Capital Management's Q3 2024 Portfolio in Review

As of Q3 2024, Prelude Capital Management held 1,616 positions worth $1.65B, up 15% from $1.44B the previous quarter. Its ten largest holdings account for 14% of the portfolio.

Prelude Capital Management deployed $127M of net new capital in Q3 2024, opening 434 new positions and adding to 384 existing holdings. Its largest new stake was Kellanova: 90,625 shares worth $7.31M.

By sector, the portfolio is most concentrated in Technology at 15% of assets, down from 17% a quarter earlier, followed by Consumer Discretionary and Healthcare.

On the sell side, the largest reduction was Western Digital, an estimated $8.43M trimmed.

  • Prelude Capital Management's largest Q3 2024 buy was Kellanova: 90,625 shares worth $7.31M.
  • Prelude Capital Management added most to Elastic in Q3 2024, an estimated $6.65M increase.
  • Prelude Capital Management's biggest Q3 2024 reduction was Western Digital, cutting an estimated $8.43M.
  • Prelude Capital Management fully exited Cerevel Therapeutics Holdings, Inc. Common Stock in Q3 2024, selling an estimated $11.1M.
  • Prelude Capital Management's ten largest holdings make up 14% of its $1.65B portfolio in Q3 2024.
  • Prelude Capital Management opened 434 new positions and closed 375 in Q3 2024.
  • Prelude Capital Management's portfolio value rose 15% quarter-over-quarter to $1.65B.

Based on Prelude Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.